Moreover, the assessment of the in vivo glucocorticoid sensitivity in MS using the expression of GR-target genes (GILZ, DUSP, FKBP) has revealed up-regulation of GR targeted genes in patients with mild to moderate disability, while patients with severe disability displayed gene transcription concentration lower than healthy controls12, supporting further GC resistance in MS patients. This evidence concerns the gene NR3C1 and myeloid sarcoma.